The etiology of metabolic and morphological changes during antiretroviral therapy: Many small pieces in a large jigsaw

AIDS Reviews

Volumn 3, Issue 2, 2001, Pages 75-81

  Moyle, G ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

Dyslipidaemia; Etiology; Glucose; HIV; Lipids; Lipodystrophy; Toxicity

Indexed keywords

ANTIRETROVIRUS AGENT; ATAZANAVIR; CD4 ANTIGEN; CYTOKINE; GLUCOSE; HORMONE; LIPID; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; TIPRANAVIR; UNCLASSIFIED DRUG; ZIDOVUDINE;

AGE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIETARY INTAKE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; EVIDENCE BASED MEDICINE; EXERCISE; GENETIC ASSOCIATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; LIFESTYLE; LIPID METABOLISM; LIPID STORAGE; LIPODYSTROPHY; METABOLIC DISORDER; MORPHOLOGY; OBESITY; REVIEW; VIRUS LOAD; VIRUS RESISTANCE;

EID: 0035203375     PISSN: 11396121     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (62)

1. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors
2. Changes in HIV-associated fat maldistribution over time
3. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy
4. Nucleoside reverse transcriptase inhibitor-induced mitochondrial toxicity as an etiology for lipodystrophy
5. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance
6. Lipodystrophy syndrome in HIV infection: What is it, what causes it and how can it be managed?
7. Mitochondrial toxicity hypothesis for lipoatrophy: A refutation
8. Lipodystrophy in patients naive to HIV protease inhibitors
9. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy
10. Lack of clinical lipodystrophy in patients receiving efavirenz + NRTI in study 006
11. Increased risk of lipodystrophy when including NRTIs in the treatment of HIV-1 infection with Pls: Results from a randomised controlled trial
12. Effects of NRTI intensification on prevalence of body composition abnormalities at week 144 of ritonavir plus saquinavir therapy in an HIV-infected cohort
13. Switching from a PI-based to a PI-sparing regimen for management of metabolic or clinical fat redistribution
14. No difference in lipodystrophy incidence in stavudine versus zidovudine nucleoside backbone: Blinded evaluation in a cohort on first line HAART
15. Body shape abnormalities in a cohort of HIV- infected patients on first-line HAART
16. Absence of association between individual thymidine analogues or non-nucleoside analogues and lipid abnormalities in HIV-1 infected persons on initial therapy
17. Stimulation of vitamin A(1) acid signaling by the HIV protease inhibitor indinavir
18. HIV protease inhibitors block human preadipocyte differentiation, but not via the PPARgamma/RXR heterodimer
19. Inducible inactivation of hepatic LRP gene by cre-mediated recombination confirms role of LRP in clearance of chylomicron remnants
20. The mechanism of insulin resistance caused by HIV protease inhibitor therapy
21. Direct effects of protease inhibitors on lipid metabolism in cultured mammalian cells
22. HIV protease inhibitors increase secretion of apolipoprotein B-lipoproteins from hepatoma cells by preventing proteosomal degradation
23. Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects
24. Metabolic effects of indinavir in healthy HIV-seronegative subjects
25. Cardiac and adipose tissue abnormalities but not diabetes in mice deficient in GLUT4
26. Changes in cortisol/DHEA ratio in HIV-infected men are related to immunological and metabolic perturbations leading to malnutrition and lipodystrophy
27. Decrease of mitochondrial DNA content in adipose tissue of HIV-1 infected patients treated with NRTIs
28. Subcutaneous adipose tissue mitochondrial DNA analysis from individuals with HAART associated lipodystrophy
29. Clinical mitochondrial genetics
30. Mitochondrial encephalomyopathies
31. Differences in postprandial lipid metabolism in patients with PI-associated and NRTI-associated lipodystrophy
32. &aq;4&aq; Dysregulation of lipid turnover is a key defect in the lipodystrophy syndrome
33. Mitochondrial function in HIV-infected patients with lipodystrophy during exercise and recovery
34. Diagnosis and interpretation of steatosis and steatohepatitis
35. Raised lactate levels are common and may be predictive of subcutaneous fat wasting
36. Effects of nucleoside reverse transcriptase inhibitors and HIV protease inhibitors on adipogenesis and adipocyte metabolism
37. Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection
38. Effects of stavudine (d4T) on mitochondrial DNA in mice
39. Mitochondrial toxicity of antiviral drugs
40. Differential expression of mitochondrial DNA replication factors in mammalian tissues
41. Anti-HIV nucleoside and nucleotide analogues (NA) and mitochondria: Is all NA toxicity mitochondrial toxicity?
42. Diverging substrate specificity of pure human thymidine kinases 1 and 2 against antiviral dideoxynucleosides
43. Expression of human mitochondrial thymidine kinase in Escherichia coli: Correlation between the enzymatic activity of pyrimidine nucleoside analogues and their inhibitory effect on bacterial growth
44. Genotoxicity and mitochondrial damage in human lymphocytic cells chronically exposed to 3′-azido-2′, 3′-dideoxythymidine
45. Effects of reverse transcriptase inhibitors on telomere length and telomerase activity in two immortalized human cell lines
46. Antioxidants rescue NRTI-injured metabolic changes in AKR/J mice
47. Lipids, lipoproteins, triglyceride clearance, and cytokines in HIV infection and the acquired immunodeficiency syndrome
48. Assessment of growth hormone dynamics in human immunodeficiency virus-related lipodystrophy
49. The glucocorticoid receptor type II complex is a target of the HIV-1 vpr gene product
50. Adipose redistribution in human immunodeficiency virus-seropositive patients: Association with CD4 response
51. Impaired glucose intolerance and dyslipidaemia as late effects after bone-marrow transplant in childhood
52. Alteration of tumor necrosis factor-alpha T-cell homeostasis following potent antiretroviral therapy: Contribution to the development of human immunodeficiency virus-associated lipodystrophy syndrome
53. Association of severe insulin resistance with both loss of limb fat and elevated serum tumor necrosis factor receptor levels in HIV lipodystrophy
54. Lipodystrophy in patients with HIV-1 infection: Effect of stopping protease inhibitors on TNF-receptor levels, insulin resistance and lipid profile
55. Tumor necrosis factor-alpha induces apoptosis of human adipose cells
56. CD36 deficiency induced by antiretroviral therapy: A predictive role in lipodystrophy
57. Defective uptake and utilization of long chain fatty acids in muscle and adipose tissues of CD36 knockout mice
58. Metformin in the treatment of HIV lipodystrophy syndrome: A randomized controlled trial
59. An open-label, randomized trial of dietary advice with or without pravastatin for the management of protease inhibitor induced hpercholesterolaemia
60. A randomised double blind study of gemfibrozil for the treatment of protease inhibitor-associated hypertriglyceridaemia
61. A pilot study of exercise training to reduce trunk fat in adults with HIV-associated fat redistribution